Weekly Roundup: October 11-15

ICYMI, some of this week’s featured content includes an exclusive interview about tralokinumab, and articles on ruxolitinib as a treatment for vitiligo, the role of diet in acne and more.


Study: AD and Out of Pocket Health Care Expenses

Atopic Dermatitis and Mental Health of Pediatric Patients

A recent study in JAMA Dermatology investigated the possible association of atopic dermatitis and mental health outcomes across childhood.

Study: AD and Out of Pocket Health Care Expenses

How are atopic dermatitis and out of pocket health care expenses related? This study aimed to find out.

EADV Releases Nemolizumab Phase 2 Data

Nemolizumab phase 2 clinical trial data for patients with prurigo nodularis and atopic dermatitis was recently released at the EADV.

AMG 451/KHK4083 Phase 2 Study Data Released

Amgen and Kyowa Kirin announce positive study data from their phase 2 trial of AMG 451/KHK4083.

Is There Liability if I Vaccinate My Staff and Something Goes Wrong?

In this month's Legal Eagle column, David J. Goldberg, MD, JD, addresses the question of what private practice dermatologist have to consider with Covid-19 vaccines.

New Data on Investigational Tralokinumab for Treatment of AD

In this exclusive video interview with Dermatology Times®, Andrew Blauvelt, MD, MBA, discusses the newest phase 3 clinical data on investigational tralokinumab as a potential treatment option in atopic dermatitis.

Roflumilast Cream Data Show Positive Outcomes for Plaque Psoriasis

Arcutis Biotherapeutics, Inc has released data from its DERMIS-1 and DERMIS-2 Phase 3 pivotal studies demonstrating that the topical significantly reduced the burden and severity of itch.

Allergan and SkinBetter Science Support Inclusive Atlas

The two companies are using their DREAM initiative to support the diverse dermatology index.

Study: Daylight PDT vs Conventional PDT for Actinic Keratosis Treatment

Researchers examine whether daylight PDT is less painful but equally as effective as conventional PDT as treatment for actinic keratosis.

Impetigo Treatment and Antimicrobial Resistance

A recent review evaluates the information provided to clinicians regarding antimicrobial resistance in impetigo treatment.

Emerging Treatment Strategies for Impetigo

With increasing antibiotic resistance to treatment, impetigo research has been driven to find newer alternative options.

The Role of Diet in Photodynamic Therapy for Actinic Keratosis

A recent study examines the role of a vegan or omnivore diet on photodynamic therapy for actinic keratosis.

Hair and Skin Diversity Examined

In this month's Cosmetic Conundrums column, Dermatology Times® Chief Medical Editor Zoe Diana Draelos, MD, explore skin and hair diversity, including physiological and characteristic differences.

Comments Offer Perspectives on Coppertone Recall

Coppertone, David Light, founder and CEO of Valisure, and Christopher Bunick, MD, PhD, share their thoughts on the sunscreen giant’s voluntary recall of 12 lots of its aerosol sunscreen after finding the presence of benzene.

Bayer Announces Voluntary Recall of OTC Antifungal Products

Bayer is recalling its Lotrimin AF and Tinactin spray products due to the presence of the carcinogen benzene.

Pointers With Dr Portela: What is Hidradenitis Suppurativa?

In this week’s Pointers with Dr Portela, the 208SkinDoc watches several TikTok videos in which creators share their experience with hidradenitis suppurativa.

Relatlimab/Nivolumab Application for Frontline Advanced Melanoma Validated by EMA

The European Medicines Agency has validated its marketing authorization application for the fixed-dose combination of relatlimab and nivolumab in the frontline treatment of adult and pediatric patients with advanced melanoma.

Study: Pediatric Usage, Drug Survival of Systemic, Phototherapy Treatments

A recent study examines systemic and phototherapy treatment utilization and drug survival in pediatric patients with psoriasis.

Monthly jobs report shows healthcare hiring stagnating

There wasn’t much change in healthcare hiring in September.